Search

Your search keyword '"Guz G"' showing total 104 results
Start Over Author "Guz G"
104 results on '"Guz G"'

7. Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome

Author

Yeter Hasan H., Derici Ulver, Arinsoy Turgay, Altok Kadriye, Erten Yasemin, and Guz Galip

Subjects
atypical hemolytic uremic syndrome, eculizumab, therapeutic plasma exchange, discontinuation, prognosis, Internal medicine, RC31-1245
Abstract

Introduction. The aim was to evaluate the effect of therapeutic plasma exchange (TPE) and eculizumab on hematological and renal survival in atypical hemolytic uremic syndrome (aHUS), and additionally, to examine the reliability of discontinuation of eculizumab treatment.

Published
2022
Full Text
View/download PDF

9. Therapeutic approach to familial Mediterranean fever: a review update

Author

Kanbay, M., Ozturk, M. A., Kasapoglu, B., Onat, A. M., Guz, G., Furst, D. E., and Ben-Chetrit, E.

Abstract

Familial Mediterranean fever (FMF) is a hereditary disorder characterised by recurrent attacks of fever with peritonitis or pleuritis, arthritis, myalgia or erysipelas-like skin lesions. The continuous inflammation in FMF is associated with increased serum amyloid A (SAA) protein which may lead to secondary amyloidosis and deposition of this insoluble protein in the kidney, gut, spleen, liver, heart etc. Therefore, treatment of patients with FMF is beneficial not only for the prevention of the acute attacks but also for improving their prognosis. In the present review we simunarise the medical literature concerning FMF treatment, including new therapeutic agents and management of colchicine-resistant patients. Three electronic databases (MEDLINE, EMBASE, and the Cochrane Library) were searched from I January 1960 to 28 February 2010 for any therapeutic approach to FMF, with MeSH headings and text words (Familial Mediterrenean Fe vet; FMF treatment, colchicine, infliximab, anakinra, SSRI). In conclusion, colchicine remains the mainstay therapeutic option in FMF It is effective in various manifestations of the disease such as fever, peritonitis and pleuritis. It prevents the development of amyloidosis. It is safe in humans regarding fertility, and can be used during pregnancy and nursing. Dose adjustment should be made in patients with renal or hepatic failure. It is less effective in arthritis or myalgia, requiring additional treatment with NSAIDs and steroids. In the few cases where FMF is resistant to colchicine oilier measures, including corticosteroids, non-biological and biological DMARDs, interferon alpha and SSRIs should be employed.

Published
2011

11. WPŁYW PROCESÓW OSIADANIA I ZANIKANIA GLEB ORGANICZNYCH MURSZOWYCH NA PROFILE PODŁUŻNE ROWÓW ODWADNIAJĄCO-NAWADNIAJĄCYCH.

Author

Oleszczuk, R., Gąsowska, M., Guz, G., Urbański, J., and Hewelke, E.

Abstract

Copyright of Acta Scientiarum Polonorum. Formatio Circumiectus is the property of Wydawnictwo Uniwersytetu Rolniczego im. Hugona Kollataja w Krakowie and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2017
Full Text
View/download PDF

14. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease

Author

Altok, Kadriye, Sindel, S, Ball, M, Ozkurt, Zübeyde Nur, Bicik, Z, Atalay, V, Erten, Y, Ozdemir, H, and Guz, G

Abstract

Atherosclerosis is a disease of: the arterial wall, with increasing wall thickness representing all early event in the progression of the disease. It has been suggested that iron overload. as assessed by increased serum ferritin concentration, may be a risk factor for atherosclerosis.

Published
2005

15. Case-based session: unusual cases in clinical practice: Wednesday 3 December 2014, 09:00-10:30 * Location: Agora

Author

Dostalova, G., primary, Hlubocka, Z., additional, Ravlykova, K., additional, Rohn, V., additional, Zeman, J., additional, Palecek, T., additional, Linhart, A., additional, Bochard Villanueva, B., additional, Fabregat-Andres, O., additional, De La Espriella-Juan, R., additional, Cubillos-Arango, A., additional, Ferrando-Beltran, M., additional, Chacon-Hernandez, N., additional, Estornell-Erill, J., additional, Perez-Bosca, J., additional, Morell-Cabedo, S., additional, Paya-Serrano, R., additional, Mediratta, A., additional, Retzer, E., additional, Decara, J., additional, Weinert, L., additional, Shah, A., additional, Lang, R. M., additional, Altun, I., additional, Guz, G., additional, Akin, F., additional, Kose, N., additional, Ilknur Altun, I., additional, Felice, T., additional, Mercieca Balbi, M., additional, Yamagata, K., additional, and Felice, H., additional

Published
2014
Full Text
View/download PDF

16. Combining clinical features and MEST-C score in IgA nephropathy may be a better determinant of kidney survival

Author

Yeter Hasan Haci, Gonul Ipek, Guz Gizem, Helvaci Ozant, Korucu Berfu, Akcay Omer Faruk, Derici Ulver, and Arinsoy Turgay

Subjects
iga nephropathy, glomerulonephritis, end stage kidney disease, glucocorticoid, oxford classification, Internal medicine, RC31-1245
Abstract

Introduction. IgA nephropathy (IgAN) is a heterogeneous disease with highly variable clinical and histopathological features. We investigated the effects of Oxford classification and clinical features on renal survival in patients with IgAN.

Published
2020
Full Text
View/download PDF

17. State financial regulation of renewable energy development

Author

Guz Natalya, Tsareva Liudmila, Adamova Irina, and Guz Grigoriy

Subjects
Environmental sciences, GE1-350
Abstract

The article considers financial incentives for the development and application of renewable energy technologies. The authors argue that state support is necessary to make renewable energy competitive with non-renewable energy. The state financial regulation of renewable energy is fixed by corresponding programme documents. Green bonds, block grants, reduced rates of customs duties, subsidies and preferential lending can be used as instruments of financial stimulation in different countries. The article points out the remaining obstacles and barriers that limit the wide application of renewable energy.

Published
2023
Full Text
View/download PDF

18. AKI - experimental models

Author

Lai, C.-F., primary, Lin, S.-L., additional, Chiang, W.-C., additional, Chen, Y.-M., additional, Kuo, M.-L., additional, Tsai, T.-J., additional, Hwang, H. S., additional, Choi, Y. A., additional, Park, K. C., additional, Yang, K. J., additional, Choi, H. S., additional, Kim, S. H., additional, Lee, S. J., additional, Chang, Y. K., additional, Kim, S. Y., additional, Yang, C. W., additional, Xiujuan, Z., additional, Yoshimura, R., additional, Matsuyama, M., additional, Chargui, J., additional, Touraine, J.-L., additional, Yoshimura, N., additional, Zulkarnaev, A. B., additional, Vasilenko, I. A., additional, Artemov, D. V., additional, Vatazin, A. V., additional, Park, S. K., additional, Kang, K. P., additional, Lee, S., additional, Kim, W., additional, Schneider, R., additional, Betz, B., additional, Moller-Ehrlich, K., additional, Wanner, C., additional, Sauvant, C., additional, Park, C. W., additional, Sohotnik, R., additional, Nativ, O., additional, Abbasi, A., additional, Awad, H., additional, Frajewicki, V., additional, Armaly, Z., additional, Heyman, S. N., additional, Abassi, Z., additional, Chen, P. Y., additional, Chen, B. L., additional, Yang, C. C., additional, Chiang, C. K., additional, Liu, S. H., additional, Abozahra, A. E., additional, Abd-Elkhabir, A. A., additional, Shokeir, A., additional, Hussein, A., additional, Awadalla, A., additional, Barakat, N., additional, Abdelaziz, A., additional, Yamaguchi, J., additional, Tanaka, T., additional, Eto, N., additional, Nangaku, M., additional, Quiros, Y., additional, Lopez-Hernandez, F. J., additional, Perez de Obanos, M. P., additional, Ruiz, J., additional, Lopez-Novoa, J. M., additional, Shin, H.-S., additional, Kim, M.-J., additional, Choi, Y.-J., additional, Ryu, E.-S., additional, Choi, H.-S., additional, Kang, D.-H., additional, Jankauskas, S. S., additional, Pevzner, I. B., additional, Zorova, L. D., additional, Babenko, V. A., additional, Morosanova, M. A., additional, Plotnikov, E. Y., additional, Zorov, D. B., additional, Huang, C.-Y., additional, Huang, T.-M., additional, Wu, V.-C., additional, Young, G.-H., additional, Chupyrkina, A. A., additional, Zorov, S. D., additional, Grande, J. P., additional, Hartono, S. P., additional, Knudsen, B. E., additional, Mederle, K., additional, Castrop, H., additional, Hocherl, K., additional, Iwakura, T., additional, Fujikura, T., additional, Ohashi, N., additional, Yasuda, H., additional, Fujigaki, Y., additional, Matsui, I., additional, Hamano, T., additional, Inoue, K., additional, Obi, Y., additional, Nakano, C., additional, Kusunoki, Y., additional, Tsubakihara, Y., additional, Rakugi, H., additional, Isaka, Y., additional, Shimomura, A., additional, Wallentin Guron, C., additional, Nguy, L., additional, Lundgren, J., additional, Grimberg, E., additional, Kashioulis, P., additional, Guron, G., additional, DiBona, G. F., additional, Nedergaard Mikkelsen, M., additional, Marcussen, N., additional, Saeed, A., additional, Edvardsson, K., additional, Lindberg, K., additional, Larsson, T., additional, Ito, K., additional, Nakashima, H., additional, Watanabe, M., additional, Abe, Y., additional, Ogahara, S., additional, Saito, T., additional, Albertoni, G., additional, Borges, F., additional, Schor, N., additional, Beresneva, O. N., additional, Parastayeva, M. M., additional, Kucher, A. G., additional, Ivanova, G. T., additional, Shved, N., additional, Rybakova, M. G., additional, Kayukov, I. G., additional, Smirnov, A. V., additional, Chen, J.-F., additional, Ni, H.-F., additional, Pan, M.-M., additional, Liu, H., additional, Xu, M., additional, Zhang, M.-H., additional, Liu, B.-C., additional, Kim, Y., additional, Choi, B. S., additional, Kim, Y. S., additional, Han, J. S., additional, Reis, L. A., additional, Christo, J. S., additional, Simoes, M. d. J., additional, Mulay, S. R., additional, Santhosh Kumar, V. R., additional, Kulkarni, O. P., additional, Darisipudi, M., additional, Lech, M., additional, Anders, H.-J., additional, Silachev, D. N., additional, Sola, A., additional, Jung, M., additional, Ventayol, M., additional, Mastora, C., additional, Buenestado, S., additional, Hotter, G., additional, Rong, S., additional, Shushakova, N., additional, Wensvoort, G., additional, Haller, H., additional, Gueler, F., additional, Morais, C., additional, Vesey, D. A., additional, Johnson, D. W., additional, Gobe, G. C., additional, Godo, M., additional, Kaucsar, T., additional, Revesz, C., additional, Hamar, P., additional, Cheng, Q., additional, Wen, J., additional, Ma, Q., additional, Zhao, J., additional, Castellano, G., additional, Stasi, A., additional, Di Palma, A. M., additional, Gigante, M., additional, Netti, G. S., additional, Curci, C., additional, Intini, A., additional, Divella, C., additional, Prattichizzo, C., additional, Fiaccadori, E., additional, Pertosa, G., additional, Grandaliano, G., additional, Gesualdo, L., additional, Wei, Q. W., additional, Jing, Q. Q., additional, Ying, N. J., additional, Dong, Q. Z., additional, Yong, G., additional, Pulkova, N. V., additional, Sukhikh, G. T., additional, Kim, S., additional, Lee, J., additional, Nam, N. J., additional, Na, K. Y., additional, Ma, S. K., additional, Joo, S. Y., additional, Kim, C. S., additional, Choi, J. S., additional, Bae, E. H., additional, Kim, S. W., additional, Cernaro, V., additional, Medici, M. A., additional, Donato, V., additional, Trimboli, D., additional, Lorenzano, G., additional, Santoro, D., additional, Montalto, G., additional, Buemi, M., additional, Longo, V., additional, Segreto, H. R. C., additional, Almeida, W., additional, Ramos, M. F., additional, Gomes, L., additional, Razvickas, C., additional, Gutberlet, M., additional, Meier, M., additional, Mengel, M., additional, Wacker, D., additional, Hueper, K., additional, Uzum, A., additional, Ersoy, R., additional, Cakalagaoglu, F., additional, Karaman, M., additional, Kolatan, E., additional, Sahin, O., additional, Yilmaz, O., additional, Cirit, M., additional, Inal, S., additional, Koc, E., additional, Okyay, G. U., additional, Pasaoglu, O., additional, Gonul, I., additional, Oyar, E., additional, Pasaoglu, H., additional, Guz, G., additional, Sabbatini, M., additional, Rossano, R., additional, Andreucci, M., additional, Pisani, A., additional, Riccio, E., additional, Choi, D. E., additional, Jeong, J. Y., additional, Kim, S. S., additional, Na, K.-R., additional, Lee, K. W., additional, Shin, Y. T., additional, Silva, A. F., additional, Teixeira, V. C., additional, Meszaros, K., additional, Koleganova-Gut, N., additional, Schaefer, F., additional, Ritz, E., additional, Walacides, D., additional, Ruskamp, N., additional, Schiffer, M., additional, Marom, O., additional, Haick, H., additional, Nakhoul, F., additional, Lv, L.-L., additional, Tang, R.-N., additional, Zhang, J.-D., additional, Ma, K.-L., additional, Chen, P.-S., additional, Ko, W.-J., additional, Misiara, G. P., additional, Coimbra, T. M., additional, Silva, G. E. B., additional, Costa, R. S., additional, Francescato, H. D. C., additional, Neto, M. M., additional, Dantas, M., additional, Olauson, H., additional, Amin, R., additional, Ponnusamy, A., additional, Goetz, R., additional, Mohammadi, M., additional, Canfield, A., additional, Kublickiene, K., additional, Rodriguez, J., additional, Reyes, E. P., additional, Cortes, P. P., additional, Fernandez, R., additional, Yoon, H. E., additional, Koh, E. S., additional, Chung, S., additional, Shin, S. J., additional, Pazzano, D., additional, Lupica, R., additional, Torre, F., additional, Costantino, G., additional, Prieto, M., additional, Gonzalez-Buitrago, J. M., additional, Lopez-Hernandez, F., additional, Morales, A. I., additional, Vicente-Vicente, L., additional, Ferreira, L., additional, Simoes, M. J., additional, Passos, C. d., additional, Schor, N. S., additional, Shimizu, M. H. M., additional, Canale, D., additional, de Braganca, A. C., additional, Andrade, L., additional, Luchi, W. M., additional, Seguro, A. C., additional, Goncalves, J., additional, Volpini, R. A., additional, Garrido, P., additional, Fernandes, J., additional, Ribeiro, S., additional, Vala, H., additional, Parada, B., additional, Alves, R., additional, Belo, L., additional, Costa, E., additional, Santos-Silva, A., additional, and Reis, F., additional

Published
2013
Full Text
View/download PDF

20. Genetic studies in renal diseases

Author

Tosetto, E., primary, Casarin, A., additional, Cristofaro, R., additional, Salviati, L., additional, Anglani, F., additional, Prot Bertoye, C., additional, Lebbah, S., additional, Daudon, M., additional, Couffignal, C., additional, Elie, C., additional, Tostivint, I., additional, Traxer, O., additional, Knebelmann, B., additional, Courbebaisse, M., additional, Bavbek Ruzgaresen, N., additional, Ceri, M., additional, Kargili, A., additional, Akdeniz, D., additional, Akcay, A., additional, Duranay, M., additional, Guz, G., additional, Testa, A., additional, Spoto, B., additional, Sanguedolce, M. C., additional, Panuccio, V., additional, Leonardis, D., additional, Tripepi, R., additional, Mafrica, A., additional, Tripepi, G., additional, Zoccali, C., additional, Mallamaci, F., additional, Pesce, F., additional, Cox, S. N., additional, Serino, G., additional, Sallustio, F., additional, Froguel, P., additional, Schena, F. P., additional, Falchi, M., additional, Boger, C., additional, and Ckd Progression Writing Group, O. B. o. t. C., additional

Published
2012
Full Text
View/download PDF

21. Peritoneal dialysis

Author

Liu, J., primary, Liu, J., additional, Liu, Y., additional, Xu, Y., additional, Zhao, X., additional, Qian, J., additional, Sun, B., additional, Xing, C., additional, Kanda, R., additional, Hamada, C., additional, Nakano, T., additional, Wakabayashi, K., additional, Io, H., additional, Horikoshi, S., additional, Tomino, Y., additional, Ishimatsu, N., additional, Miyamoto, T., additional, Morimoto, H., additional, Nakamata, J., additional, Baba, R., additional, Kanegae, K., additional, Serino, R., additional, Kabashima, N., additional, Otsuji, Y., additional, Doi, Y., additional, Tamura, M., additional, Kusumoto, T., additional, Fukami, K., additional, Yamagishi, S.-I., additional, Ueda, S., additional, Kaida, Y., additional, Hazama, T., additional, Nakayama, Y., additional, Ando, R., additional, Obara, N., additional, Okuda, S., additional, Matsumoto, M., additional, Furuno, Y., additional, Bang-Gee, H., additional, Mazzotta, L., additional, Rosati, A., additional, Carlini, A., additional, Henriques, V. T., additional, Zangiacomi Martinez, E., additional, Divino-Filho, J. C., additional, Pecoits-Filho, R., additional, Cardeal Da Costa, J. A., additional, Gama Axelsson, T., additional, Lindholm, B., additional, Carrero, J. J., additional, Heimburger, O., additional, Stenvinkel, P., additional, Qureshi, A. R., additional, Akazawa, M., additional, Uno, T., additional, Kanda, E., additional, Maeda, Y., additional, Aktsiali, M., additional, Antonopoulou, S., additional, Tsiolaki, K., additional, Bakirtzi, N., additional, Patrinou, A., additional, Georgopoulou, M., additional, Liaveri, P., additional, Afentakis, N., additional, Tsirpanlis, G., additional, Hasegawa, T., additional, Nishiwaki, H., additional, Hirose, M., additional, Komukai, D., additional, Tayama, H., additional, Koiwa, F., additional, Yoshimura, A., additional, Lui, S. L., additional, Lui, S., additional, Yung, S., additional, Tang, C., additional, Ng, F., additional, Lo, W. K., additional, Chan, T. M., additional, Koo, H. M., additional, Doh, F. M., additional, Yoo, D. E., additional, Oh, H. J., additional, Yoo, T.-H., additional, Choi, K. H., additional, Kang, S.-W., additional, Han, D. S., additional, Han, S. H., additional, Fernandes, N., additional, Bastos, M. G., additional, Gianotti Franco, M. R., additional, Chaoubah, A., additional, Gloria Lima, M. D., additional, Kang, S., additional, Do, J., additional, Cho, K., additional, Park, J., additional, Yoon, K., additional, Chen, J.-B., additional, Cheng, B.-C., additional, Chen, T.-C., additional, Su, Y.-J., additional, Wu, C.-H., additional, Park, Y., additional, Jeon, J., additional, Tsikeloudi, M., additional, Pateinakis, P., additional, Patsatsi, K., additional, Manou, E., additional, Sotiriadis, D., additional, Tsakiris, D., additional, Teixeira, L., additional, Rodrigues, A., additional, Carvalho, M. J., additional, Cabrita, A., additional, Mendonca, D., additional, Bruschi, M., additional, Candiano, G., additional, Santucci, L., additional, Luzio, S., additional, Cannavo, R., additional, Ghiggeri, G. M., additional, Verrina, E., additional, Varadarajan, Y., additional, Raju, B., additional, Cho, K.-H., additional, Park, J.-W., additional, Yoon, K.-W., additional, Kim, T.-W., additional, Kimmel, M., additional, Braun, N., additional, Latus, J., additional, Alscher, M. D., additional, Struijk, D., additional, Van Esch, S., additional, Krediet, R. T., additional, Van den Beukel, T., additional, Hoekstra, T., additional, Tirapani, L., additional, De Andrade Bastos, K., additional, Bastos, M., additional, Dekker, F., additional, Yasuhisa, T., additional, Kanai, H., additional, Harada, K., additional, Kawai, Y., additional, Sugiyama, H., additional, Ito, Y., additional, Tsuruya, K., additional, Yoshida, H., additional, Maruyama, H., additional, Goto, S., additional, Nakayama, M., additional, Nakamoto, H., additional, Morinaga, H., additional, Matsuo, S., additional, Makino, H., additional, DI Gioia, M. C., additional, Gallar, P., additional, Laso, N., additional, Rodriguez, I., additional, Cobo, G., additional, Oliet, A., additional, Hynostroza, J., additional, Herrero, J. C., additional, Mon, C., additional, Ortiz, M., additional, Vigil, A., additional, Tomo, T., additional, Portoles, J., additional, Uta, S., additional, Tato, A. M., additional, Lopez-Sanchez, P., additional, Rivera, M., additional, Rodriguez-Pena, R., additional, Del Peso, G., additional, Ortega, M., additional, Felipe, C., additional, Tsampikaki, E., additional, Aperis, G., additional, Kaikis, A., additional, Paliouras, C., additional, Karvouniaris, N., additional, Maragaki, M., additional, Alivanis, P., additional, Kortus-Gotze, B., additional, Hoferhusch, T., additional, Hoyer, J., additional, Martino, F., additional, Kaushik, M., additional, Rodighiero, M. P., additional, Creapldi, C., additional, Ronco, C., additional, Lacquaniti, A., additional, Donato, V., additional, Fazio, M. R., additional, Lucisano, S., additional, Cernaro, V., additional, Lupica, R., additional, Buemi, M., additional, Aloisi, C., additional, Bavbek Ruzgaresen, N., additional, Secilmis, S., additional, Yilmaz, H., additional, Akcay, A., additional, Duranay, M., additional, Akalin, N., additional, Altiparmak, M. R., additional, Trabulus, S., additional, Yalin, A. S., additional, Ataman, R., additional, Serdengecti, K., additional, Schneider, K., additional, Bator, B., additional, Niko, B., additional, Peter, F., additional, Ulmer, C., additional, Joerg, L., additional, Martin, K., additional, Dagmar, B., additional, German, O., additional, Fabian, R., additional, Juergen, D., additional, Stephan, S., additional, Dominik, A., additional, Fritz, P., additional, Rettenmaier, B., additional, Hirschburger, S., additional, Segerer, S., additional, Biegger, D., additional, Lang, T., additional, Ott, G., additional, Habib, M., additional, Korte, M., additional, Hagen, M., additional, Dor, F., additional, Betjes, M., additional, Zietse, R., additional, Scharpf, C., additional, Chang, T. I., additional, Shin, D. H., additional, Han, D.-S., additional, Choi, H. Y., additional, Lee, Y. K., additional, Kim, B. S., additional, Yoo, T. H., additional, Park, H. C., additional, Lee, H. Y., additional, Horimoto, N., additional, Tuji, K., additional, Kitamura, S., additional, Isshiki, R., additional, Iwagami, M., additional, Tsutsumi, D., additional, Mochida, Y., additional, Ishioka, K., additional, Oka, M., additional, Maesato, K., additional, Moriya, H., additional, Ohtake, T., additional, Hidaka, S., additional, Kobayashi, S., additional, Higuchi, C., additional, Tanihata, Y., additional, Ishii, M., additional, Sugimoto, H., additional, Sato, N., additional, Kyono, A., additional, Ogawa, T., additional, Nishimura, H., additional, Otsuka, K., additional, Do, J.-Y., additional, Du Halgouet, C., additional, Latifa, A., additional, Anne Sophie, V., additional, Emmanuel, D., additional, Christine, R., additional, Francois, V., additional, Grzelak, T., additional, Czyzewska-Majchrzak, L., additional, Kramkowska, M., additional, Witmanowski, H., additional, Czyzewska, K., additional, Janda, K., additional, Krzanowski, M., additional, Dumnicka, P., additional, Sulowicz, W., additional, Rroji, M., additional, Seferi, S., additional, Barbullushi, M., additional, Likaj, E., additional, Petrela, E., additional, Thereska, N., additional, Cabiddu, G., additional, Dessi, E., additional, Arceri, A., additional, Laura, P., additional, Manca, E., additional, Conti, M., additional, Cao, R., additional, Pani, A., additional, Liao, C.-T., additional, Vega Vega, O., additional, Mendoza de la Garza, A., additional, Correa-Rotter, R., additional, Ueda, A., additional, Nagai, K., additional, Morimoto, M., additional, Hirayama, A., additional, Owada, S., additional, Tonozuka, Y., additional, Saito, C., additional, Yamagata, K., additional, Matsuda, A., additional, Tayama, Y., additional, Iwanaga, M., additional, Noiri, C., additional, Hatano, M., additional, Kiba, T., additional, Kanozawa, K., additional, Katou, H., additional, Hasegawa, H., additional, Mitarai, T., additional, Ros-Ruiz, S., additional, Fuentes-Sanchez, L., additional, Jironda-Gallegos, C., additional, Gutierrez-Vilches, E., additional, Garcia-Frias, P., additional, Hernandez-Marrero, D., additional, Lee, S., additional, Lai, X., additional, Chen, W., additional, Guo, Z., additional, Braide, M., additional, Cristina, V., additional, Popa, S. G., additional, Maria, M., additional, Eugen, M., additional, DI Loreto, P., additional, Spahia, N., additional, Sanchez Macias, L. O., additional, Lares Castellanos, K. I., additional, Hernandez Pacheco, J. A., additional, Correa Rotter, R., additional, Pedro Ventura, A., additional, Olivia, S., additional, Joana, V., additional, Francisco, F., additional, Maria Joao, C., additional, Antonio, C., additional, Rodrigues, A. S., additional, Atas, N., additional, Erten, Y., additional, Onec, K., additional, Inal, S., additional, Topal, S., additional, Akyel, A., additional, Celik, B., additional, Okyay, G. U., additional, Tavil, Y., additional, Zeiler, M., additional, Monteburini, T., additional, Agostinelli, R. M., additional, Marinelli, R., additional, Santarelli, S., additional, Yaylaci, C., additional, Sahin, G., additional, Guz, G., additional, Sindel, S., additional, Pinho, A., additional, Malho Guedes, A., additional, Fragoso, A., additional, Carreira, H., additional, Pinto, I., additional, Bernardo, I., additional, Leao, P., additional, Kusnierz-Cabala, B., additional, Krasniak, A., additional, Chowaniec, E., additional, Tabor-Ciepiela, B., additional, Turkmen, K., additional, Ozbek, O., additional, Kayrak, M., additional, Samur, C., additional, Guler, I., additional, Tonbul, H. Z., additional, Rusai, K., additional, Herzog, R., additional, Kratochwill, K., additional, Kuster, L., additional, Aufricht, C., additional, Meier, C.-M., additional, Fliser, D., additional, Schilling, M. K., additional, Klingele, M., additional, Fukasawa, M., additional, Takeda, M., additional, Kamiyama, M., additional, Song, Y. R., additional, Kim, H. J., additional, Kim, S. G., additional, Kim, J.-K., additional, Noh, J. W., additional, Yoon, J. W., additional, and Koo, J.-R., additional

Published
2012
Full Text
View/download PDF

22. Transplantation: clinical studies

Author

Crespo, M., primary, Collado, S., additional, Mir, M., additional, Hurtado, S., additional, Cao, H., additional, Barbosa, F., additional, Serra, C., additional, Hidalgo, C., additional, Faura, A., additional, Garcia de Lomas, J., additional, Montero, M., additional, Horcajada, J. P., additional, Puig, J. M., additional, Pascual, J., additional, Ulusal Okyay, G., additional, Uludag, K., additional, Sozen, H., additional, Arman, D., additional, Dalgic, A., additional, Guz, G., additional, Fraile, P., additional, Garcia-Cosmes, P., additional, Rosado, C., additional, Gonzalez, C., additional, Tabernero, J. M., additional, Costa, C., additional, Saldan, A., additional, Astegiano, S., additional, Terlizzi, M. E., additional, Messina, M., additional, Bergallo, M., additional, Segoloni, G., additional, Cavallo, R., additional, Schwarz, A., additional, Grosshennig, A., additional, Heim, A., additional, Broecker, V., additional, Haller, H., additional, Linnenweber, S., additional, Liborio, A. B., additional, Mendoza, T. R., additional, Esmeraldo, R. M., additional, Oliveira, M. L. M. B., additional, Nogueira Paes, F. J. V., additional, Silva Junior, G. B., additional, Daher, E. F., additional, Hodgson, K., additional, Baharani, J., additional, Fenton, A., additional, Mjoen, G., additional, Hartmann, A., additional, Reisaeter, A., additional, Midtvedt, K., additional, Dahle, D. O., additional, Holdaas, H., additional, Shabir, S., additional, Lukacik, P., additional, Bevins, A., additional, Basnayake, K., additional, Bental, A., additional, Hughes, R. G., additional, Cockwell, P., additional, Burrows, R., additional, Hutchison, C. A., additional, Varma, P., additional, Kumar, A., additional, Hooda, A., additional, Badwal, S., additional, Barrios, C., additional, Crespo, M., additional, Fumado, L., additional, Frances, A., additional, Arango, O., additional, Pawlik, A., additional, Chudek, J., additional, Kolonko, A., additional, Wilk, J., additional, Jalowiecki, P., additional, Wiecek, A., additional, Teplan, V., additional, Kralova-Lesna, I., additional, Mahrova, A., additional, Racek, J., additional,  tollova, M., additional, Maggisano, V., additional, Caracciolo, V., additional, Solazzo, A., additional, Montanari, M., additional, Della Grotta, F., additional, Nakazawa, D., additional, Nishio, S., additional, Nakagaki, T., additional, Ishikawa, Y., additional, Ito, M., additional, Shibazaki, S., additional, Shimoda, N., additional, Miura, M., additional, Morita, K., additional, Nonomura, K., additional, Koike, T., additional, Locsey, L., additional, Seres, I., additional, Sztanek, F., additional, Harangi, M., additional, Padra, J., additional, Asztalos, L., additional, Paragh, G., additional, Rodriguez-Reimundes, E., additional, Soler-Pujol, G., additional, Diaz, C. H., additional, Davalos-Michel, M., additional, Vilches, A. R., additional, Laham, G., additional, Stavem, K., additional, Norby, G., additional, Tutal, E., additional, Canver, B., additional, Can, S., additional, Sezer, S., additional, Colak, T., additional, Paschoalin, R., additional, Barros, X., additional, Duran, C., additional, Torregrosa, J. V., additional, Tellez, E., additional, Marin, M., additional, Smalcelj, R., additional, Smalcelj, A., additional, Claes, K., additional, Petit, T., additional, Bammens, B., additional, Kuypers, D., additional, Naesens, M., additional, Vanrenterghem, Y., additional, Evenepoel, P., additional, Gerhart, M. K., additional, Colbus, S., additional, Seiler, S., additional, Grun, O., additional, Fliser, D., additional, Heine, G. H., additional, Vincenti, F., additional, Grinyo, J., additional, Larsen, C., additional, Medina Pestana, J., additional, Dong, Y., additional, Thomas, D., additional, Charpentier, B., additional, Luna, E., additional, Martinez, R., additional, Cerezo, I., additional, Ferreira, F., additional, Cubero, J., additional, Villa, J., additional, Martinez, C., additional, Garcia, C., additional, Rodrigo, E., additional, Santos, L., additional, Pinera, C., additional, Quintela, E., additional, Ruiz, J. C., additional, Fernandez-Fresnedo, G., additional, Palomar, R., additional, Gomez-Alamillo, C., additional, Martin de Francisco, A. L., additional, Arias, M., additional, Nainan, G., additional, del Carmen Rial, M., additional, Steinberg, S., additional, Kamar, N., additional, Durrbach, A., additional, Becker, T., additional, Florman, S., additional, Lang, P., additional, Schnitzler, M., additional, Duan, T., additional, Block, A., additional, Sawosz, M., additional, Cieciura, T., additional, Durlik, M., additional, Perkowska, A., additional, Sikora, P., additional, Beck, B., additional, De Mauri, A., additional, Brambilla, M., additional, Stratta, P., additional, Chiarinotti, D., additional, De Leo, M., additional, Attou, S., additional, Arzour, H., additional, Boudrifa, N., additional, Mekhlouf, N., additional, Gaouar, A., additional, Merazga, S., additional, Kalem, K., additional, and Haddoum, F., additional

Published
2011
Full Text
View/download PDF

30. Children's understanding of the distinction between real and apparent emotion.

Author

Harris, Paul L., Donnelly, Kara, Guz, Gabrielle R., Pitt-Watson, Rosemary, Harris, P L, Donnelly, K, Guz, G R, and Pitt-Watson, R

Subjects
EMOTIONS & cognition, CHILD psychology, CHILD development, AGE distribution, COGNITION, COMPARATIVE studies, CONCEPTS, EMOTIONS, RESEARCH methodology, MEDICAL cooperation, RESEARCH, EVALUATION research
Abstract

2 experiments examined children's understanding of the distinction between real and apparent emotion. In Experiment 1, 6- and 10-year-old children listened to stories in which it would be appropriate for the story protagonist to feel either a positive or negative emotion but to hide that emotion. Subjects were asked to say both how the protagonist would look and how the protagonist would really feel, and to justify their claims. The results indicated that 6- and 10-year-olds alike could distinguish quite accurately between real and apparent emotion, although 10-year-olds were somewhat better at justifying this distinction. In Experiment 2, a slightly modified procedure was used to test 4- and 6-year-olds. Again, 6-year-olds demonstrated their grasp of the difference between real and apparent emotion, and even 4-year-olds showed a limited grasp of the distinction. The findings are discussed in relation to recent research concerning children's concept of mind, their grasp of the appearance-reality distinction, their ability to produce complex, embedded justifications, and their ideas about emotion. [ABSTRACT FROM AUTHOR]

Published
1986
Full Text
View/download PDF

33. Changes in intraocular pressure, and corneal and retinal nerve fiber layer thickness during hemodialysis

Author

Galip Guz, Zeynep Aktas, Sengul Ozdek, Merih Önol, Umut Asli Dinc, Dinc, U.A., Ozdek, S., Aktas, Z., Guz, G., Onol, M., and Yeditepe Üniversitesi

Subjects
Adult, Male, Intraocular pressure, medicine.medical_specialty, genetic structures, medicine.medical_treatment, Nerve fiber layer, Retinal nerve fiber layer thickness, Retina, Cornea, chemistry.chemical_compound, Young Adult, Nerve Fibers, Renal Dialysis, Ophthalmology, medicine, Humans, Statistical analysis, Intraocular Pressure, Aged, Scanning laser polarimeter, business.industry, Body Weight, Osmolar Concentration, Total body, Retinal, Middle Aged, eye diseases, Surgery, Corneal thickness, medicine.anatomical_structure, chemistry, Hemodialysis, Chronic renal failure, Kidney Failure, Chronic, Female, sense organs, business
Abstract

The aim of this study is to evaluate the changes in intraocular pressure (IOP), central corneal thickness (CCT), and retinal nerve fiber layer thickness (RNFLT) in patients with chronic renal failure undergoing hemodialysis (HD). A complete ophthalmological examination together with IOP, CCT, and RNFLT measurements were performed for each patient both before and after HD sessions. RNFLT parameters were detected by scanning laser polarimeter. Total body weight and serum osmolality were also measured. Only the left eyes were recruited for statistical analysis. Thirty-three eyes of 33 patients were enrolled in the study. Mean IOP decreased from 14.7 plusmn; 3.1 to 13.4 plusmn; 2.4 mmHg after HD (paired t test, P = 0.005). Mean CCT also decreased significantly after HD, from 556.5 plusmn; 33.5 to 550.2 plusmn; 34.6 mu;m (paired t test, P = 0.002). CCT change in the left eyes was found to be correlated with total body volume loss (Pearson correlation test, R = 0.391 and P = 0.030). Considering RNFLT parameters before and after HD, no significant alterations were detected by scanning laser polarimeter (paired t test, P(gt;0.05). We conclude that IOP may decrease to some extent after HD. CCT may be affected by fluid loss after HD sessions, with a resultant decrease in corneal thickness. In patients with chronic renal failure undergoing HD, RNFLT parameters can be measured as in healthy individuals. Underestimation of intraocular pressure values after HD sessions should be taken into account, especially in patients with chronic renal failure. © Springer Science+Business Media B.V. 2010.

Published
2010

34. Heterologous Versus Homologous COVID-19 Boosters: Immune Response Outcomes in Renal Transplant Recipients.

Author

Yildiz Y, Yasar E, Ozturk E, Karakan MS, Helvaci O, Ozger HS, Cemre Araz Z, Yildiz PA, Dikmen AU, Caglar K, Dizbay M, Derici U, and Guz G

Subjects
Humans, Female, Male, Middle Aged, Prospective Studies, Adult, Mycophenolic Acid therapeutic use, Mycophenolic Acid administration & dosage, Vaccination, Immunosuppressive Agents therapeutic use, Immunosuppressive Agents administration & dosage, Kidney Transplantation adverse effects, COVID-19 immunology, COVID-19 prevention & control, Antibodies, Viral blood, Immunization, Secondary, Transplant Recipients statistics & numerical data, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, SARS-CoV-2 immunology
Abstract

We aimed to investigate the immune responses to homologous and heterologous COVID-19 booster vaccinations in renal transplant recipients (RTRs) and to identify factors affecting these responses. In this prospective multicenter observational study, we measured the antibody kinetics of 90 RTRs using the chemiluminescent microparticle immunoassay method. The mean age of participants was 45.2 ± 11.4 years, with 35.6% being female. On the 42nd day after the first vaccine dose, the median antibody level was 16.7 (IQR 2.5-249.5) AU/mL, and the seropositivity rate was 60% (n = 36). Mycophenolic acid (MFA) (OR: 0.087, 95% CI: 0.024-0.311) and ACE inhibitor use (OR: 0.203, 95% CI: 0.052-0.794) were identified as independent factors affecting seropositivity. Patients who received the Pfizer/BioNTech booster had significantly higher antibody levels compared to those who received the CoronaVac/Sinovac booster (p = 0.021). Additionally, a significantly higher rate of COVID-19 positivity was observed among patients who received the CoronaVac/Sinovac booster (p = 0.031). Heterologous COVID-19 booster vaccination is significantly more effective than homologous inactivated booster vaccination in enhancing immune responses and preventing new infections in RTRs. MFA and ACE inhibitor usage were independent factors affecting seropositivity. Additional COVID-19 vaccine doses are needed in this patient group., (Journal of Medical Virology© 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.)

Published
2024
Full Text
View/download PDF

35. Effects of incremental peritoneal dialysis with low glucose-degradation product neutral pH solution on clinical outcomes.

Author

Yeter HH, Altunok M, Cankaya E, Yildirim S, Akturk S, Bakirdogen S, Akoğlu H, Bulut M, Sahutoglu T, Erdut A, Ozkahya M, Koc Y, Tunca O, Kara E, Erek M, Polat M, Akagun T, and Guz G

Subjects
Humans, Male, Female, Middle Aged, Prospective Studies, Hydrogen-Ion Concentration, Aged, Treatment Outcome, Peritoneal Dialysis, Continuous Ambulatory, Kidney Failure, Chronic therapy, Retrospective Studies, Adult, Glucose, Peritoneal Dialysis, Dialysis Solutions chemistry
Abstract

Purpose: Incremental peritoneal dialysis (IPD) could decrease unfavorable glucose exposure results and preserve (RKF). However, there is no standardization of dialysis prescriptions for patients undergoing IPD. We designed a prospective observational multi-center study with a standardized IPD prescription to evaluate the effect of IPD on RKF, metabolic alterations, blood pressure control, and adverse outcomes., Methods: All patients used low GDP product (GDP) neutral pH solutions in both the incremental continuous ambulatory peritoneal dialysis (ICAPD) group and the retrospective standard PD (sPD) group. IPD patients started treatment with three daily exchanges five days a week. Control-group patients performed four changes per day, seven days a week., Results: A total of 94 patients (47 IPD and 47 sPD) were included in this study. The small-solute clearance and mean blood pressures were similar between both groups during follow-up. The weekly mean glucose exposure was significantly higher in sPD group than IPD during the follow-up (p < 0.001). The patients with sPD required more phosphate-binding medications compared to the IPD group (p = 0.05). The rates of peritonitis, tunnel infection, and hospitalization frequencies were similar between groups. Patients in the sPD group experienced more episodes of hypervolemia compared to the IPD group (p = 0.007). The slope in RKF in the 6th month was significantly higher in the sPD group compared to the IPD group (65% vs. 95%, p = 0.001)., Conclusion: IPD could be a rational dialysis method and provide non-inferior dialysis adequacy compared to full-dose PD. This regimen may contribute to preserving RKF for a longer period., (© 2024. The Author(s), under exclusive licence to Springer Nature B.V.)

Published
2024
Full Text
View/download PDF

36. Pretransplant Parathyroidectomy in Patients with Severe Secondary Hyperparathyroidism and Long-Term Effectiveness After Kidney Transplantation.

Author

Akcay OF, Yeter HH, Yuksel O, and Guz G

Subjects
Humans, Male, Female, Middle Aged, Adult, Retrospective Studies, Treatment Outcome, Follow-Up Studies, Parathyroidectomy, Hyperparathyroidism, Secondary surgery, Hyperparathyroidism, Secondary etiology, Kidney Transplantation, Bone Density
Abstract

Kidney transplantation (KT) is the best option for patients with end-stage renal disease, but recipients still have legacy bone mineral disease from the pretransplant period, especially patients with severe secondary hyperparathyroidism (sHPT). Patients who had severe sHPT and underwent KT were analyzed retrospectively. Two groups were identified (patients with severe sHPT who had parathyroidectomy or calcimimetic before KT). Bone mineral density (BMD) was measured in the first year and last follow-up at the femoral neck, total hip, and lumbar spine using the dual-energy X-ray absorptiometry (DXA). Persistent hyperparathyroidism (perHPT) incidence was significantly higher in the calcimimetic group (75% vs. 40%, p=0.007). In patients with parathyroidectomy, BMDs were higher at femoral neck (0.818±0.114 vs. 0.744±0.134, p=0.04) and lumbar spine (1.005±0.170 vs. 0.897±0.151, p=0.01) at the first assessment. The BMD comparison between patients treated with parathyroidectomy and calcimimetic found a significant difference only in the femoral neck at second evaluation (0.835±0.118 vs. 0.758±0.129; p=0.03). In multivariate, linear regression revealed a positive association between the last BMD of the femoral neck with body mass index (CC: 0.297, 95% CI, 0.002-0.017) and parathyroidectomy (CC: 0.319, 95% CI, 0.021-0.156). Parathyroidectomy is associated with a significantly better femoral neck BMD and a lower incidence of perHPT in patients with severe sHPT., Competing Interests: The authors declare that they have no conflict of interest., (Thieme. All rights reserved.)

Published
2024
Full Text
View/download PDF

37. Comparison of homologous and heterologous inactivated and mRNA vaccination programme against SARS-CoV-2 in dialysis patients.

Author

Yasar E, Yildiz Y, Ozturk E, Gok Oguz E, Coskun Yenigun E, Ozturk R, Helvaci O, Ozger HS, Keles M, Karacin C, Ugras Dikmen A, Caglar K, Duranay M, Ayli MD, Dizbay M, Erten Y, Guz G, and Derici U

Subjects
Humans, Male, Female, Middle Aged, Aged, Immunization, Secondary, Antibodies, Viral blood, Peritoneal Dialysis adverse effects, Vaccination methods, Vaccines, Inactivated administration & dosage, Vaccines, Inactivated immunology, Adult, COVID-19 prevention & control, COVID-19 immunology, Renal Dialysis adverse effects, BNT162 Vaccine administration & dosage, BNT162 Vaccine immunology, SARS-CoV-2 immunology, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines immunology
Abstract

Aim: To evaluate the vaccine response and the effect of the booster dose on COVID-19 positivity in haemodialysis (HD) and peritoneal dialysis (PD) patients who received and did not receive BNT162b2 as a booster dose after two doses of CoronaVac., Methods: The study included 80 PD and 163 HD patients, who had been administered two doses of the CoronaVac. Antibody levels were measured on Days 42 and 90 after the first dose. Measurements were repeated on Day 181 after the first dose in the patients that received two vaccine doses and on Day 28 after the third dose in those that also received the booster dose. Antibody levels below 50 AU/mL were considered negative., Results: The seropositivity rate was similar in the HD and PD group on Days 42 and 90 (p = 0.212 and 0.720). All patients were seropositive in the booster group. The antibody level was lower in the patients that received CoronaVac as the booster compared to those administered BNT162b2 in HD and PD groups (p < 0.001 and 0.002). COVID-19 positivity was detected in 11 patients (7 = had not received the booster dose, 4 = had received third dose of CoronaVac). The multivariate analysis revealed that as age increased, COVID-19 positivity also increased (OR: 1.080, 95% CI: 1.017 - 1.146, p = 0.012), while booster dose administration decreased this positivity (OR: 0.113, 95% CI: 0.028 - 0.457, p = 0.002)., Conclusion: Our results may indicate the need for additional vaccination doses in patients with HD and PD. Our findings indicate a higher antibody response in dialysis patients with heterologous BNT162b2 as a booster dose after two doses of CoronaVac compared to homologous CoronaVac., (© 2024 Asian Pacific Society of Nephrology.)

Published
2024
Full Text
View/download PDF

38. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials.

Author

Arici M, Altun B, Araz M, Atmaca A, Demir T, Ecder T, Guz G, Gogas Yavuz D, Yildiz A, and Yilmaz T

Abstract

This scoping review prepared by endocrinology and nephrology experts aimed to address the significance of finerenone, as a novel therapeutic option, in diabetic kidney disease (DKD), based on the biological prospect of cardiorenal benefit due to non-steroidal mineralocorticoid receptor antagonist (MRA) properties, and the recent evidence from the finerenone phase 3 program clinical trials. The importance of finerenone in slowing DKD progression was critically reviewed in relation to the role of MR overactivation in the pathogenesis of cardiorenal disease and unmet needs in the current practice patterns. The efficacy and safety outcomes of finerenone phase III study program including FIDELIO-DKD, FIGARO-DKD and FIDELITY were presented. Specifically, perspectives on inclusion of patients with preserved estimated glomerular filtration rate (eGFR) or high albuminuria, concomitant use of sodium-glucose co-transporter-2 inhibitor (SGLT2i) or glucagon-like peptide 1 receptor agonist (GLP-1 RA), baseline glycated hemoglobin (HbA1c) level and insulin treatment, clinically meaningful heart failure outcomes and treatment-induced hyperkalemia were addressed. Finerenone has emerged as a new therapeutic agent that slows DKD progression, reduces albuminuria and risk of cardiovascular complications, regardless of the baseline HbA1c levels and concomitant treatments (SGLT2i, GLP-1 RA, or insulin) and with a favorable benefit-risk profile. The evolving data on the benefit of SGLT2is and non-steroidal MRAs in slowing or reducing cardiorenal risk seem to provide the opportunity to use these pillars of therapy in the management of DKD, after a long-period of treatment scarcity in this field. Along with recognition of the albuminuria as a powerful marker to detect those patients at high risk of cardiorenal disease, these important developments would likely to impact standard-of-care options in the setting of DKD., Competing Interests: MArici reports payment or honoraria for lectures, presentations, speakers bureaus, publication writing or educational events from Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Menarini, MSD, Novo Nordisk, Sandoz, Sanofi, and participation on a Data Safety Monitoring Board or Advisory Board for Astra Zeneca, Bayer, Boehringer Ingelheim, and Novo Nordisk. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Arici, Altun, Araz, Atmaca, Demir, Ecder, Guz, Gogas Yavuz, Yildiz and Yilmaz.)

Published
2024
Full Text
View/download PDF

39. Association of longitudinal high-sensitive C-reactive protein levels with changing membrane characteristics in peritoneal dialysis.

Author

Korucu B, Deger SM, Yeter H, Akcay OF, Cimen Y, Dogan B, Kiraci M, Giritlioglu A, Kanber S, Erdemir MB, Cicekli S, and Guz G

Subjects
Humans, C-Reactive Protein, Retrospective Studies, Peritoneum metabolism, Dialysis Solutions metabolism, Glucose metabolism, Biological Transport, Peritoneal Dialysis methods, Peritonitis metabolism
Abstract

Background: Increasing peritoneal permeability with ultrafiltration and solute removal inadequacy is a challenging issue in peritoneal dialysis (PD). Decreasing permeability is less frequent but also results in diminished solute clearance. We evaluated the association between longitudinal high-sensitive C-reactive protein (hs-CRP) values and the change in transport characteristics of the peritoneal membrane in PD patients., Methods: This is a retrospective, single-center study of incident PD patients. An increase or decrease in peritoneal transport status is defined as two or more categories of a rise or decline in the peritoneal equilibration test (PET) from their baseline during follow-up. The 4-h dialysate/plasma creatinine ratio was used to classify transport characteristics. Hs-CRP values were obtained from the routine annual examinations of the patients., Results: Baseline demographics, residual kidney function, frequency of high glucose-containing dialysate, and icodextrin use were similar between the groups. Total episodes of peritonitis within the first 5 years of follow-up were higher in stable transporters than in increased and decreased transporters (p = 0.009). Stable transporters' mean hs-CRP values did not change within 5 years (Wilks' λ = 0.873, F (2.317, 180.740) = 2.210, p = 0.10). Increased and decreased transporters' hs-CRP values significantly raised over the years (Wilks' λ = 0.422, F (1.979, 77.163) = 3.405, p = 0.04 and Wilks' λ = 0.558, F (3.673, 66.107) = 4.396, p = 0.001, respectively)., Conclusions: Our study shows that the peritoneal membrane may change into different characteristics in many patients over time, despite very low peritonitis frequencies and similar baseline characteristics that may be significantly affected by systemic inflammation., (© 2022 International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.)

Published
2023
Full Text
View/download PDF

40. First Composite Woman-to-Woman Facial Transplantation in Turkey: Challenges and Lessons to Be Learned.

Author

Ozmen S, Findikcioglu K, Sibar S, Tuncer S, Ayhan S, Guz G, Unal Y, and Aslan S

Subjects
Humans, Female, Young Adult, Adult, Turkey, Immunosuppression Therapy, Facial Transplantation, Vascularized Composite Allotransplantation
Abstract

Abstract: After the first face transplantation from woman to woman we performed in our clinic, it was aimed to eliminate the lack of knowledge about the subject in the literature by transferring our experiences and long-term results to the problems we had with the patient. A 20-year-old patient underwent partial osteomyocutaneous facial transplant (22nd facial transplant), which included 2 functional units of the face. The patient had no major problems in the early period and had a good aesthetic appearance. In the postoperative period, the patient ended her social isolation and adopted the transplanted face.In the late period, secondary surgical interventions, management of the problems caused by immunosuppression, and the patient's living in a remote location to our clinic were the difficulties encountered. Six revision surgeries were performed after the transplantation. Due to immunosuppression, opportunistic infections and metabolic problems required intermittent hospitalization. The patient died at the end of 56 months because of complications secondary to immunosuppression.A successful transplant involves the management of long-term problems rather than a successful tissue transfer in the early period. In today's conditions, long-term success can be achieved with a good patient compliance, as well as each team member should take an active role in the team at the transplantation centers. More case series are needed to adapt the standard treatment and follow-up protocols for solid organ transplantations for composite tissue allotransplantations. This will be possible by sharing the results and experiences transparently in the centers where face transplantation is performed worldwide., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

41. The Effects of CNI and Mtori-Based Regimens on Bone Mineral Density After Renal Transplantation.

Author

Korucu B, Yeter H, and Guz G

Subjects
Bone Density, Calcineurin Inhibitors therapeutic use, Humans, Immunosuppressive Agents therapeutic use, Middle Aged, Kidney Transplantation adverse effects, Osteoporosis drug therapy, Osteoporosis etiology, Osteoporosis prevention & control
Abstract

Background : Since glucocorticoids are used in low maintenance doses today, the relationship between calcineurin inhibitors (CNI) and osteoporosis has become clinically significant in osteoporosis after solid organ transplantation. However, there is evidence that the mammalian target of rapamycin inhibitors (mTORi) may be beneficial via osteoclast inhibition. Objective : The bone mineral density (BMD) changes are investigated in renal transplant patients under CNI or mTORi-based maintenance regimens during the first five-year post-transplant course. Methods : This study consists of thirty-three renal allograft recipients with less than one year of dialysis history. The exclusion criteria were: being older than 50 years old, history of bisphosphonate use, parathyroidectomy, CNI-mTORi switch after the post-transplant third month, diuretic use, and history of malignancy. First and fifth-year BMD scores and simultaneous laboratory parameters were evaluated. Results : CNI (n=21) and mTORi group (n=12) had similar demographics, dialysis vintages, first and fifth-year serum parathormone, calcium, phosphate, magnesium, alkaline phosphatase, and 25-OH-vitamin D levels. The femur neck scores of the CNI group decreased from -0.82 (±0.96) to -1.52 (±0.92) (p=0.020). We observed a significant decrease in the CNI group compared to the mTORi group [-0.70 (±0.68) and 0.30 (±0.36), respectively; p<0.01] when the BMD score changes were evaluated among years. The mean femur neck score of the mTORi group increased insignificantly from -1.13 (±0.65) to -0.82 (±0.56) at the fifth-year DXA scan (p=0.230). Similar trends were also observed in L1-4 scores. Conclusion : Our study suggests that CNI-based treatment is associated with decreased femur neck BMD scores, and mTORi-based treatment tends to be beneficial in the post-transplant five-year follow-up., (© 2022 Berfu Korucu et al., published by Sciendo.)

Published
2022
Full Text
View/download PDF

42. Factors Affecting Bone Health in Kidney Transplant Recipients: Klotho Gene Single-Nucleotide Polymorphisms and Other Clinical Features.

Author

Yeter HH, Helvaci O, Korucu B, Gonen S, Guz G, and Derici U

Subjects
Female, Humans, Male, Bone Density, Risk Factors, Treatment Outcome, Polymorphism, Single Nucleotide, Bone Diseases, Metabolic complications, Hyperparathyroidism etiology, Kidney Transplantation adverse effects, Osteonecrosis complications, Osteoporosis complications
Abstract

Objectives: Posttransplant bone diseases are a major cause of morbidity in kidney transplant recipients. We investigated the relationship between klotho gene single-nucleotide polymorphisms and bone diseases after kidney transplant. We also aimed to identify possible risk factors for development of bone disease., Materials and Methods: The study consisted of 251 kidney transplant recipients (164 men and 87 women) with minimum follow-up of 3 years after kidney transplant. Patients with prolonged immobilization, malignancy, parathyroidectomy, glomerular filtration rates less than 30 mL/min/1.73 m², hypo- or hyperthyroidism, and treatment with drugs that affect bone metabolism were excluded. We investigated the relationship between 6 single-nucleotide polymorphisms of the klotho gene (rs480780, rs211234, rs576404, rs211235, rs9536314, and rs1207568) and development of osteoporosis, avascular bone necrosis, and persistent hyperparathyroidism., Results: Longer dialysis treatment (odds ratio, 1.13; P = .002) and rs211235 single-nucleotide polymorphism in the klotho gene (odds ratio, 9.87; P = .001 for GG genotype) were significantly associated with persistent hyperparathyroidism. A higher magnesium level was detected as a protective factor from development of persistent hyperparathyroidism (odds ratio, 0.19; P = .009). Persistent hyperparathyroidism was defined as a risk factor for development of osteopenia/osteoporosis (odds ratio, 2.76; P = .003) and avascular bone necrosis (odds ratio, 2.52; P = .03). Although the rs480780 (odds ratio, 8.73; P = .04) single-nucleotide polymorphism in the klotho gene was defined as a risk factor for development of osteopenia/osteoporosis, none of the klotho single-nucleotide polymorphisms was found to be associated with development of avascular bone necrosis., Conclusions: Persistent hyperparathyroidism could be an important indicator for development of bone disease in kidney transplant recipients. Also, some of the klotho gene single-nucleotide polymorphisms are associated with higher risk for bone disease after kidney transplant.

Published
2022
Full Text
View/download PDF

44. Obstetric and long-term graft outcomes in pregnant kidney transplant recipients: A single-center experience.

Author

Akcay OF, Yeter HH, Karcaaltincaba D, Bayram M, Guz G, and Erten Y

Subjects
Creatinine, Female, Humans, Pregnancy, Transplant Recipients, Kidney Transplantation adverse effects, Pre-Eclampsia, Pregnancy Complications epidemiology, Pregnancy Complications etiology
Abstract

Background: Kidney transplantation (KT) is the best option for many women with end-stage renal disease desiring pregnancy. The aim of this study was to investigate obstetric and graft outcomes among KT recipient women in our center., Methods: Maternal and fetal data were assessed in 29 pregnancies of 18 female KT recipients. Each patient was matched with two controls without pregnancy history for factors known to affect graft function. According to pre-pregnancy levels, serum creatinine and eGFR slope in the gestational and postpartum periods were calculated as percentages., Results: The main maternal and fetal complications were preeclampsia (38%) and preterm births (38%), respectively. Pregnancy (odds ratio [OR]: 5.09; p = .02), proteinuria in the third trimester (OR: 5.52; p = .02), proteinuria in postpartum third months (OR: 7.4; p = .008) and stable creatinine levels in the first 6 months of pregnancy (OR: 11.25 p = .03) were associated with graft dysfunction. Postpartum first year eGFR decline (-16.8% vs. -6.7%; p = .04) and second-year eGFR decline (-18.5% vs. -8.3%; p = .04) were significantly higher in the pregnancy group than those matched controls., Conclusion: Pregnancy after KT is associated with high rates of maternal and fetal complications. The sustained decline of eGFR may suggest an increased risk of graft loss compared to recipients with similar clinical characteristics., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2021
Full Text
View/download PDF

45. Effects of phospholipase A 2 receptor and thrombospondin type-1 domain-containing 7A expression in glomerular basement membranes on treatment response and renal outcome in membranous nephropathy.

Author

Yeter HH, Isik Gonul I, Eraslan E, Karacalik C, Ogut B, and Guz G

Subjects
Adult, Biopsy, Disease Progression, Female, Glomerular Basement Membrane pathology, Glomerular Filtration Rate, Glomerulonephritis, Membranous physiopathology, Glomerulonephritis, Membranous therapy, Humans, Immunoglobulin G metabolism, Immunosuppressive Agents therapeutic use, Male, Middle Aged, Proportional Hazards Models, Recurrence, Retrospective Studies, Sex Factors, Treatment Outcome, Glomerular Basement Membrane metabolism, Glomerulonephritis, Membranous metabolism, Glomerulonephritis, Membranous pathology, Receptors, Phospholipase A2 metabolism, Thrombospondins metabolism
Abstract

Background: The aim of this study was to define the clinicopathologic features of phospholipase A 2 receptor (PLA 2 R) and/or thrombospondin type-1 domain-containing 7A (THSD7A) associated membranous nephropathy(MN) focusing on their impact to disease relapse and response to treatment., Methods: A total of 201 patients were enrolled for baseline clinical and histopathological features and 102 patients with a clinical follow-up for more than 1 year were evaluated for outcomes. Immunohistochemical staining was performed with PLA 2 R and THSD7A antibodies on kidney biopsies and glomerular staining was evaluated., Results: PLA 2 R expression was observed in 75% of the patients' biopsies; however, THSD7A expression was present only in 7 patients' biopsies (3.5%). No significant difference was found between histopathological and clinical features of PLA 2 R positive and negative patients, collectively. Glomerular PLA 2 R expression was significantly associated with complete and complete/partial remission with first-line treatment; however, overall complete, and complete/partial remission rates did not differ from PLA 2 R negative patients (p = 0.2 and p = 0.8). Male gender, the presence of IgG4 staining and a necessity of immunosuppressive treatment were significantly associated with glomerular PLA 2 R expression. One patient, who developed end-stage renal disease, had glomerular expression for both PLA 2 R and THSD7A. Three patients with THSD7A-positive MN achieved complete remission., Conclusions: The probability of achieving complete remission is high in patients with PLA 2 R-positive MN for whom the relapse rate was also higher. The overall renal outcome did not differ from PLA 2 R negative cases. Low incidence of THSD7A-positive MN reduces the possibility of future randomized controlled trials.

Published
2021
Full Text
View/download PDF

46. The reliability and success of peritoneal dialysis during the COVID-19 pandemic.

Author

Yeter HH, Gok Oguz E, Akcay OF, Karaer R, Yasar E, Duranay M, Ayli MD, and Guz G

Subjects
Adult, Anxiety epidemiology, COVID-19 prevention & control, COVID-19 transmission, Cross-Sectional Studies, Depression epidemiology, Female, Humans, Kidney Failure, Chronic complications, Kidney Failure, Chronic psychology, Male, Middle Aged, Reproducibility of Results, Treatment Outcome, COVID-19 epidemiology, Kidney Failure, Chronic therapy, Peritoneal Dialysis
Abstract

We evaluated the symptoms, changes in laboratory findings during the novel coronavirus disease (COVID-19) pandemic, and the effect of depression in patients with peritoneal dialysis (PD). This is an observational and cross-sectional study. All patients were asked to fill the clinical assessment form and Beck depression and anxiety inventory. Also, the last two laboratory evaluations during this period were examined. A total of 123 patients performing PD were included. None of the patients were diagnosed with COVID-19. In the total study population, parathyroid hormone (PTH), serum albumin, phosphorus and ferritin levels significantly elevated at the end of 97 ± 31 days. PTH and phosphorus levels remained stable in remote monitoring automated PD (RM-APD) group (p = 0.4 and p = 0.5), they tended to increase in continuous ambulatory PD group and significantly increased in automated PD group (p = 0.09 and p = 0.01 for PTH and p = 0.06 and p = 0.001 for phosphorus, respectively). Moderate to severe depression was associated with dyspnoea, weight gain more than 5 kg, fatigue, palpitation and increased anxiety. PD is a reliable and successful form of dialysis and can be safely administered even if hospital access is restricted. Also, RM-APD may be a better choice because of providing more stable bone-mineral metabolism. Moreover, evaluating depression and anxiety is essential for the accurate clinical assessment., (© 2020 Wiley Periodicals LLC.)

Published
2021
Full Text
View/download PDF

47. Kidney biopsy in the elderly: diagnostic adequacy and yield.

Author

Helvacı Ö, Korucu B, Gonul Iİ, Arınsoy T, Guz G, and Derici U

Subjects
Adult, Age Factors, Aged, Biopsy adverse effects, Biopsy statistics & numerical data, Female, Humans, Male, Middle Aged, Postoperative Complications epidemiology, Retrospective Studies, Kidney pathology
Abstract

Purpose: The number of kidney biopsies (KB) performed in elderly patients has been increasing. Safety and usefulness of elderly KB have been well established, whereas much less is known about diagnostic adequacy and yield in this patient population., Methods: We performed a retrospective study of KBs in 428 patients from April 2015 to December 2017 at an academic institution. We compared KB from 50 patients aged over 64 (elderly) with KB from 378 patients aged between 18 and 64., Results: Gender ratio, body mass index, systolic and diastolic BP, creatinine values, incidences of AKI at the time of biopsy, INR/aptt values, and platelets were similar between the two groups. eGFR and number of transplant biopsies were lower in the elderly biopsy group. The glomerular yield was similar between the two groups (22 ± 14 vs. 22 ± 13, p = 0.869). The likelihood of obtaining more than ten glomeruli was 87% and 88%, respectively, without a significant difference. Inadequate samples were encountered in 6% of the elderly and 5.6% of the non-elderly KB, again without a significant difference. Samples taken by nephrologist had higher glomerular yield for both groups (25 ± 13 vs. 18 ± 12 overall, 26 ± 14 vs. 18 ± 14 for elderly, p < 0.001 both). Inadequate biopsies were lower in the nephrologist group when all patients were considered (3% vs. 9%, p = 0.025). Results were numerically similar for the elderly patients, but the difference was not statistically significant (2% vs. 8%, p = 0.322). No deaths occurred in both arms. Minor complications were not different for each group (4.5% vs. 4%). There were no major complications in elderly patients. However, the difference did not reach statistical significance., Conclusion: The world is aging, leading to an increased number of KB in older patients. KB in the elderly is a safe, effective, and an indispensable tool for the nephrologist. This study suggests there is no need to fear lower diagnostic adequacy in the decision making of a KB for an elderly patient.

Published
2021
Full Text
View/download PDF

49. A very rare pathogen in peritoneal dialysis peritonitis: Serratia liquefaciens .

Author

Helvaci O, Hızel K, Guz G, Arinsoy T, and Derici U

Subjects
Aged, Anti-Bacterial Agents therapeutic use, Fatal Outcome, Humans, Male, Peritonitis diagnosis, Peritonitis drug therapy, Renal Dialysis adverse effects, Serratia Infections diagnosis, Serratia Infections drug therapy, Treatment Outcome, Peritoneal Dialysis adverse effects, Peritonitis microbiology, Serratia Infections microbiology, Serratia liquefaciens isolation & purification
Abstract

Peritoneal dialysis (PD) peritonitis has been decreasing in frequency in recent years. However, it still causes significant morbidity and mortality. Nearly 1%-6% of all peritonitis attacks result in death. Hospitalizations, loss of PD access, and intravascular catheter insertion for hemodialysis are some examples of morbidity. Approximately 15%-20% of the infectious mortality of PD patients is attributed to peritonitis. The responsible pathogens are usually Gram-positive bacteria, but unusual pathogens may be present. Prognosis is worse when Gram-negative and fungal pathogens are involved. We report a case of Serratia liquefaciens peritonitis due to defiance of hygienic practices which presented with severe abdominal pain and fever and led to loss of PD access.

Published
2019
Full Text
View/download PDF

50. [An ethics call to include pregnant women in research: Reflections from the Global Forum on Bioethics in Research].

Author

Saenz C, Alger J, Beca JP, Belizán JM, Cafferata ML, Guzmán JAC, Candanedo P JE, Duque L, Figueroa L, Garcés A, Gresh L, Gubert IC, Guilhem D, Guz G, Kaltwasser G, Lescano AR, Luna F, Cardelli AAM, Mastroleo I, Melamed IN, Del Carpio Toia AM, Palacios R, Palma GI, Salas SP, Sandoval X, de Siqueira SS, Vásquez H, and de Vega BMV

Subjects
Female, Humans, Pregnancy, Bioethical Issues, Biomedical Research ethics, Patient Selection ethics
Published
2017

Catalog

Books, media, physical & digital resources
See catalog results